Aurobindo Pharma to Acquire Lannett for INR 2,185 Cr to Expand US Capacity

The acquisition aims to expand the US manufacturing base, CDMO business, and ADHD generics portfolio.

Aurobindo Pharma, through its US subsidiary Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100% membership interest in US-based complex generics manufacturer Lannett Company LLC for $250 million (approximately INR 2,185 crore).

In a regulatory filing to the stock exchanges, the Hyderabad-based pharmaceutical company confirmed that the acquisition is being made from Lannett Seller Holdco, Inc. The transaction is expected to be completed within 8 to 12 months.

Aurobindo Pharma stated that the acquisition is expected to be accretive to the extent of INR 5 per share for Aurobindo Global.

Focus on ADHD Portfolio and US-Based Capacity Expansion

The company said the proposed acquisition would help it onboard a complementary portfolio in ADHD, strengthen its CDMO (contract development and manufacturing organization) business, and expand its manufacturing footprint in the US.

Lannett Company operates a DEA-compliant cGMP facility in Seymour, Indiana, with an annual production capacity of 3.6 billion tablets. The company is known for its capabilities in controlled substances—specifically non-opioids—and generic liquid formulations.

According to Aurobindo, Lannett has built strong expertise in the ADHD therapeutic segment over the years, which aligns with Aurobindo's strategic direction in the US generics market.

Revenue Track Record and Strategic Context

The Trevose-headquartered Lannett Company reported an annual turnover of INR 2,744 crore in FY23, INR 2,499 crore in FY24, and INR 2,674 crore in FY25 (April to March).

The acquisition comes at a time when the current US administration has increased pressure on pharmaceutical manufacturers to localize supply chains and invest more in domestic manufacturing. The deal is expected to support Aurobindo’s long-term US growth strategy amid shifting policy dynamics.

Stay tuned for more such updates on Digital Health News